WHAT Exactly Is the CJC-1295?
The compound known as CJC-1295 is a synthetic analogue of the hormone known as GHRH, which stands for growth hormone releasing hormone. It has been discovered to be highly effective in increasing the secretion of growth hormone and IGF-1, without having a detrimental effect on the pulsatility of GH secretion, which is a positive finding.
Because of its increased specificity as a GHRH, CJC-1295 is frequently coupled with ipamorelin in clinical trials. Increases in development hormone release are produced by this peptide, just like those produced by other peptides in its family; however, this peptide does not cause an increase in hunger, nor does it cause an increase in adrenalin, serotonin, prolactin, or aldosterone. When coupled with ipamorelin, it has been discovered that this particular peptide is extremely well tolerated and produces optimal results.
Pituitary is the gland that is stimulated.
HOW CJC-1295 ACTS IN THE BODY OF THE PATIENT
CJC 1295 has several positive effects on the body, such as the following:
- Hormone release and IGF-1 levels have both increased, but there has been no accompanying rise in prolactin.
- Weight Gain and Length Gain Resulting from Higher Synthesis Of proteins in the Body
- Amplification of the Growth of Muscle
- Densification of the bone tissue
- Enhanced Capabilities of the Immune System
- Enhanced Capabilities of Thinking and Remembering
- Increased Quantities of Collagen Produced
- A greater reduction in body fat
- Enhanced Capacity for the Repair and Regeneration of Cells
CJC-1295 encourages slow-wave deep sleep, which is responsible for the maximum level of both muscle development and memory storage and renewal. This deep sleep is necessary for the highest level.
CJC 1295: GHRH & DAC
The hypothalamus is responsible for the production of GHRH, also known as growth hormone releasing hormone. This causes a pulsatile release of growth hormone (GH) from the pituitary gland, which is caused by its pulsatile release from the hypothalamus. The half-life of GHRH is only a few minutes, which is quite a short amount of time. Half-life is defined as the amount of time needed to remove half of the drug from the blood. The shorter the half-life, the more quickly the chemical is eliminated from the body, which in turn results in the substance having less of an impact on the body.
The active section of GHRH consists of the first 29 amino acids in the protein. They are offered for sale as a synthetic peptide that goes by the name Sermorelin. Additional modifications were made to sermorelin in order to shorten its half-life to thirty minutes. This is referred to as the CJC 1295. The CJC-1295 formula underwent additional modification when the DAC (Drug Affinity Complex) was incorporated into it. Because DAC binds to albumin, which is a blood protein, the half-life of the compound is extended to eight days. It is known by the name CJC 1295 + DAC. CJC 1295 can also be compounded into a non-DAC form, which simulates a more natural physiologic GH surge each night. This form of the drug can also be made.
Because the DAC only binds to albumin for a longer period of time, patients only need to receive injections once or twice per week rather than daily. However, due to its extended half-life and relatively stable blood level, it is able to give a steady stimulus for the release of GH from the pituitary gland via the GHRH receptor, which is counter to how things are supposed to work. This may result in a decrease in the GH pulse amplitude, which in turn will lead to a reduction in the activation of GH tissue.
Using CJC 1295 Without Risk
If you are taking a long-acting CJC molecule, it is recommended that you take a “hormone holiday” of three months every three to six months in order to give your pituitary gland time to “recover.” During the holiday season, the combination of CJC 1295 and DAC is replaced by sermorelin.
The so-called “hormone holidays” may also help reduce the possibility of acquiring GH resistance. This resistance, also known as insensitivity, could be the result of the formation of antibodies that bind to and inactivate GH, or it could be the result of a decrease in the number of GH receptors present on tissues (down-regulation). These are purely theoretical concerns at this point because no extensive research over extended periods of time have been conducted to shed light on the issues.
Injection site reactions (such as irritation, erythema, induration, discomfort, and itching), headache, diarrhoea, vasodilation (such as flushing, warmth, and transitory hypotension), nausea, and abdominal pain are all potential adverse events to CJC-1295.